Kymera Therapeutics

Kymera Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Business Update

Proof-of-mechanism and proof-of-biology established for first-in-class, oral IRAK4 degrader, KT-474,  in Single Ascending Dose portion of Phase 1 healthy volunteer trial with  up to 96% degradation in blood and up to 97% inhibition of cytokines FDA clearance of Investigational New Drug Application